Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir

29 Mar 2024

Abstract excerpt

Abstract Although vaccines are available for SARS-CoV-2, antiviral drugs such as nirmatrelvir are still needed, particularly for individuals in whom vaccines are less effective, such as the immunocompromised, to prevent severe COVID-19. Here we report an α-ketoamide-based peptidomimetic inhibitor of the SARS-CoV-2 main protease (M pro ), designated RAY1216. Enzyme inhibition kinetic analysis shows that RAY1216...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to Influenza Virus Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38553607
DOI: 10.1038/s41564-024-01618-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvirPMID 38553607Read ↗

Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitorSemantic proximity Read ↗

Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitorSemantic proximity Read ↗

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-M <sup>Pro</sup> inhibitors with potent in vivo efficacySemantic proximity Read ↗

An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.Semantic proximity Read ↗

Next-generation inhibitors of SARS-CoV-2 Mpro overcome the deficiencies of Paxlovid.Semantic proximity Read ↗

An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivoSemantic proximity Read ↗

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacySemantic proximity Read ↗

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of ConcernSemantic proximity Read ↗

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to NirmatrelvirSemantic proximity Read ↗

Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvirSemantic proximity Read ↗

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332)Semantic proximity Read ↗

Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivirSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.